The future is arriving fast for the life science industry. Convergence is happening along the entirety of the industry value chain, blurring the boundaries between pharma, biotech, generics,
Advanced technologies and materials, once the realm of science fiction, are now starting to emerge and can be expected to play a much greater role in the research efforts of life science companies in the future. Emerging market companies are expanding and edging their way to the top table as innovator drug companies.
What will the life science company of the future look like? How will the industry be transformed?
If you missed 2014's event a snapshot of the two-days can be viewed below:
SPEAKERS INCLUDED:
 |
Joseph Jimenez Chief Executive Officer Novartis |
Stefan Oschmann Member of the Executive Board, CEO Pharma Merck |
||||
| Michael Doherty Global Head, Pharma Regulatory Affairs Hoffmann La- Roche |
Bahija Jallal Executive Vice President, AstraZeneca Head, MedImmune |
|||||
| Christian Hogg Executive Director and Chief Executive Officer Hutchison China MedTech Limited |
|
|
Dr Flemming Ornskov
Chief Executive Officer
Shire
|
|||
| Simon Stevens Chief Executive Officer NHS England |
Brent Saunders President and CEO Actavis |
|||||
The FT Global Pharmaceutical and Biotechnology conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives, 'feel the pulse' of the industry, and network with peers across the sector.
